Schering Corporation

Hans Reimann

William Charney

Jan Ilavsky

Aris P Bayan

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

Olga Sarre

Mohammad Mehdi Nafissi-Varchei

Robert S Jaret

Everninomicin B, C or D may be converted to amino derivatives by reductive means. The amino derivatives may, subsequently, be converted to novel N-acyl, N-alkyl or N,N-dialkyl derivatives. Alternatively, everninomicins B, C or D may be converted to N-acyl-N-hydroxylamino derivatives also by reductive means. The derivatives so-produced and the non-toxic pharmaceutically acceptable cationic salts thereof are novel and are antibacterial agents.

Aminoeverninomicin and derivatives thereof

Described herein are novel monoesters of rosamicin, also known as Antibiotic 67-694. Also described is a process for the preparation of such esters by the selective solvolysis of diester precursors. The monoesters are broad spectrum antibacterial agents but are generally more effective against gram-positive bacteria.

Monoesters of rosamicin for eliciting an antibacterial response

Rosamicin is an antibiotic elaborated by Micromonospora rosaria. The compounds described herein are antibacterial derivatives of rosamicin. Also described are processes for the preparation of these antibacterial derivatives from rosamicin.

Rosamicin derivatives and method of using same

Novel monoesters of rosamicin

A mutant strain of Micromonospora purpurea herein designated M. purpurea JI-20 elaborates an antibiotic complex comprising gentamicin and at least two novel antibiotic substances namely Antibiotic JI-20A and Antibiotic JI-20B. The so-produced antibiotics have an adverse effect upon the growth of gram-positive and gram-negative bacteria.

Antibiotic compositions and methods from micromonospora purpurea JI-20

Antibiotic from micromonospora purpurea JI-20

Growing community of inventors

Wayne, NJ, United States of America

Hans Reimann